Tarveda Therapeutics
Tingting Wang has worked in various roles since 2011. In 2011, they were an Intern at China Agricultural University, where they successfully completed a gene cloning project. In 2014, they were an Intern at Advanced Manufacture Technology Center, China Academy of Machinery Science & Technology (CAMTC), where they researched processing techniques used in a sewage disposal plant. From 2016 to 2019, they were a Research Associate at Beijing SIFANG CTM pharmaceutical Co., Ltd., where they performed raw/auxiliary materials and drug product testing. In 2019, they were a Research Associate at Takeda, where they were actively involved in the performance of formulation development activities for vaccines. Since 2021, they have been a Research Associate III at Tarveda Therapeutics, where they conduct a PD research study including lysate preparation, BCA assay, Western blot and Elisa, and performs HPLC to demonstrate formulation stability and dose verification.
Tingting Wang obtained a Master's degree in Bioengineering and Biomedical Engineering from Northeastern University between 2016 and 2018.
This person is not in any teams
This person is not in any offices
Tarveda Therapeutics
Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies.